GLP1R and diabetic kidney disease: We are the first to notice that MHR remains a risk factor for DKD even in patients taking medications with renoprotective effects (ACEI/ARB, SGLT2i, GLP-1 RA) and lipid-lowering medications that could influence HDL-C levels.